东曜药业（1875.HK）项目推介

东曜药业致力于成为行业领先、客户信赖的生物医药最佳合作伙伴。

凭借丰富的实践经验和成熟的技术平台及质量体系，东曜药业与国内外制药公司开展多元的战略合作，提供药物开发生产一站式CDMO解决方案，帮助客户加速生物药特别是抗体偶联药（ADC）的开发和生产，赋能产业高质量发展。

东曜药业拥有符合GMP规范的大规模生物药商业化生产基地，配备多条完整的上下游产线，总产能已突破20,000 L；公司已搭建ADC一体化平台，具备核心研发技术优势，可实现ADC抗体/抗体中间体、原液、制剂等关键生产环节集中一地完成，降低转移成本并减少监管风险；目前，公司已建立符合商业化生产的质量管理体系，并已支持多个上市产品的商业化生产。东曜药业拥有成熟稳定的核心团队以及良好的服务口碑，向客户提供品质卓越的专业服务。

BioDlink (Stock Code: 1875.HK) is dedicated to becoming the industry leading and trusted biopharmaceutical best partner for global clients.

With extensive practical experience, mature technical platforms and robust quality system, BioDlink has developed diversified strategic partnerships with domestic and international pharmaceutical companies to provide one-stop CDMO solutions for drug development and manufacturing, which help customers to accelerate the development and manufacturing of biologics, especially antibody-drug conjugates (ADCs), empowering to achieve high-quality development for the industry.

**
BioDlink has established a large-scale commercial GMP production base for biological drugs which has equipped with multiple complete upstream and downstream production lines, with a total manufacturing capacity exceeding 20,000 L. The company has established an integrated platform for antibody-drug conjugates (ADCs), which can complete key production processes such as antibodies, linker and drug substance to be completed in one place, reducing transfer costs and regulatory risks. Currently, BioDlink has established a quality management system in line with commercial manufacturing, which has successfully supported the commercial production of several marketed products. BioDlink has a mature, stable core team and good reputation for professional, which can provide customers with excellent professional services.**